ÂÜÀòÂÒÂ×

Alan G. Levin was appointed to the Board in February 2020. In addition to his 20-year career at Pfizer, where he served as Chief Financial Officer, Mr. Levin served as Chief Financial Officer of Endo Pharmaceuticals, Inc. over a five-year period where the company experienced a nearly 400 percent increase in its market capitalization. He currently serves on the Board of Directors of Diffusion Pharmaceuticals, Inc., a development-stage company focused on therapeutics to enhance the effectiveness of treatments for stroke and cancer, and on the advisory board of Auven Therapeutics, a global private equity fund that acquires and pursues accelerated development of breakthrough therapeutic drugs, prior to licensing them to commercial partners.

Mr. Levin is an audit committee financial expert, as defined by the Securities and Exchange Commission, and is a certified public accountant. He holds a bachelor’s degree from Princeton University and a master’s degree from New York University’s Stern School of Business.